ValuEngine cut shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a buy rating to a hold rating in a research report report published on Thursday morning, ValuEngine reports.

A number of other brokerages also recently issued reports on VNDA. BidaskClub downgraded Vanda Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Thursday, January 24th. Cantor Fitzgerald downgraded Vanda Pharmaceuticals from an overweight rating to a neutral rating and dropped their price target for the company from $38.00 to $30.00 in a research report on Wednesday, February 6th. Stifel Nicolaus reiterated a buy rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 6th. Oppenheimer dropped their price target on Vanda Pharmaceuticals from $29.00 to $21.00 in a research report on Thursday, February 14th. Finally, TheStreet downgraded Vanda Pharmaceuticals from a b- rating to a c+ rating in a research report on Thursday, February 7th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $34.00.

Shares of VNDA opened at $16.65 on Thursday. The stock has a market cap of $876.51 million, a PE ratio of 34.69, a price-to-earnings-growth ratio of 5.05 and a beta of 0.51. Vanda Pharmaceuticals has a 12-month low of $13.88 and a 12-month high of $33.44.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, February 13th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.22. The firm had revenue of $53.04 million during the quarter, compared to the consensus estimate of $51.56 million. Vanda Pharmaceuticals had a return on equity of 9.80% and a net margin of 13.05%. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.04) EPS. On average, sell-side analysts forecast that Vanda Pharmaceuticals will post 0.22 earnings per share for the current year.

In related news, CFO James Patrick Kelly sold 8,751 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $19.88, for a total value of $173,969.88. Following the completion of the sale, the chief financial officer now owns 218,497 shares in the company, valued at approximately $4,343,720.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Mihael Hristos Polymeropoulos sold 38,166 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $19.41, for a total value of $740,802.06. Following the completion of the sale, the chief executive officer now owns 1,217,136 shares of the company’s stock, valued at approximately $23,624,609.76. The disclosure for this sale can be found here. Insiders sold a total of 59,274 shares of company stock valued at $1,164,127 in the last 90 days. 7.80% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in VNDA. BlackRock Inc. lifted its position in Vanda Pharmaceuticals by 78.3% in the 3rd quarter. BlackRock Inc. now owns 8,845,222 shares of the biopharmaceutical company’s stock worth $202,999,000 after buying an additional 3,884,298 shares during the last quarter. Glenmede Trust Co. NA lifted its position in Vanda Pharmaceuticals by 328,291.4% in the third quarter. Glenmede Trust Co. NA now owns 1,766,746 shares of the biopharmaceutical company’s stock valued at $40,545,000 after purchasing an additional 1,766,208 shares during the last quarter. Vanguard Group Inc lifted its position in Vanda Pharmaceuticals by 18.8% in the third quarter. Vanguard Group Inc now owns 3,969,954 shares of the biopharmaceutical company’s stock valued at $91,111,000 after purchasing an additional 629,086 shares during the last quarter. Vanguard Group Inc. lifted its position in Vanda Pharmaceuticals by 18.8% in the third quarter. Vanguard Group Inc. now owns 3,969,954 shares of the biopharmaceutical company’s stock valued at $91,111,000 after purchasing an additional 629,086 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Vanda Pharmaceuticals by 175.5% in the third quarter. Bank of New York Mellon Corp now owns 590,671 shares of the biopharmaceutical company’s stock valued at $13,556,000 after purchasing an additional 376,301 shares during the last quarter. Institutional investors own 99.33% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Recommended Story: Buy-Side Analysts

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.